MPLT MapLight Therapeutics, Inc. Insider Trading

CMO Erin Pennock Foff sells 15.0K shares ($549.3K) via pre-arranged 10b5-1 plan at MPLT

Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, executed 2 separate sales totaling 15,000 shares for $549,303.60 on 2026-07-15 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-29. The blended average transaction price was $36.62, while the current stock price stands at $37.87, which is -6.3% from the 52-week high of $40.43. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-determined execution rather than a contemporaneous market decision. Her post-transaction holdings of 331.1K shares represent a -4.3% reduction from her pre-transaction position of 346.1K shares. The company remains unprofitable, reporting net income of $-60.7M over its most recent full fiscal year.

MapLight CEO Kroeger sells 118,235 shares for $3.2M under 10b5-1 plan; stock down 20.4% from 52-week high

Christopher A. Kroeger, CEO of MapLight Therapeutics, executed two separate sales on 2026-05-18 totaling 118,235 shares for $3,214,999.73, reducing his holdings to 1,394,094 shares (a -7.8% reduction). The transaction was executed under a 10b5-1 trading plan adopted on 2025-12-29, meaning the sales were scheduled and non-discretionary. The stock currently trades at $26.50, down 20.4% from its 52-week high of $33.28 and down 11.8% over the past 30 days, though it has appreciated 53.6% over the past 90 days. The company reported a net loss of $60,668,000.00 for its most recent full fiscal year. While the CEO retained 1,394,094 shares post-transaction, the scheduled nature of the 10b5-1 sales means timing considerations do not apply to this filing.

CEO Christopher Kroeger sells nearly 68,500 shares for ~$1.95M across three days as stock rises from depressed levels.

Christopher Kroeger, MapLight's CEO, executed a substantial liquidation of approximately 68,500 shares over three days in early May, totaling nearly $1.95 million. The stock has rebounded sharply from deeply depressed levels over the prior quarter, and Kroeger's sales occurred well above what appear to be support levels established during the recovery. However, his prior two sales at this company were poorly timed—the stock rose after both exits—raising questions about whether his current sales represent genuine conviction about overvaluation or simply represent a large liquidation that happens to occur during a strong price period. MapLight remains unprofitable with significant quarterly losses, so the company's fundamentals have not improved materially. This is Kroeger's third consecutive filing consisting of sales, with no open-market purchases during his tenure as CEO, suggesting a consistent pattern of exiting rather than adding to his position.

CFO Setia Vishwas sells over $1M in MapLight shares across three trading days despite unprofitable fundamentals

Setia Vishwas, MapLight's Chief Financial Officer, executed a substantial sale totaling approximately $1.02 million across three consecutive trading days in early May, offloading roughly nine percent of his holdings. The sales occurred at prices ranging from $27.36 to $30.12 per share. This liquidation is notable because it runs counter to what a senior financial executive typically does during a company turnaround—MapLight is currently unprofitable with significant losses in its most recent quarter, suggesting the CFO may be prioritizing near-term liquidity or reducing exposure rather than signaling confidence in a recovery narrative. The sheer size and rapid execution of the sale distinguishes it from routine equity adjustments, warranting attention from shareholders holding the stock in hopes of a profitability inflection.

Chief Medical Officer sells approximately $1.4M in MapLight shares over three days amid unprofitable fundamentals.

Erin Pennock, Chief Medical Officer of MapLight Therapeutics, executed a substantial multi-day sale totaling approximately $1.4 million across three trading days in early May. The sales ranged across a 10% band of share prices, suggesting either a programmatic liquidation or opportunistic selling into strength rather than panic dumping at a single price. This timing and execution warrant scrutiny given that the company is unprofitable with significant ongoing losses, raising the question of whether the CMO is rebalancing a concentrated position during an attractive window or has shifted sentiment about the company's near-term prospects. As a C-suite officer with direct operational insight into the company's medical and clinical direction, any material position reduction—particularly one of this scale—typically signals either portfolio diversification or a loss of confidence in the near-term trajectory. The contrast between the CMO's role (typically central to biotech value creation) and the company's heavy losses creates ambiguity: this could be routine tax-motivated or portfolio rebalancing by someone still optimistic about long-term value, or it could reflect growing skepticism about path to profitability. Deep analysis of other insider activity, recent operational updates, or clinical developments would clarify whether this is an outlier or part of a broader pattern.

MapLight CSO Lillie James Woodruff sells ~18% of holdings across three days, totaling $1.47M

Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, liquidated a substantial block of shares across three consecutive trading days, with the sale totaling approximately $1.47 million and representing roughly eighteen percent of her holdings. The sales occurred at prices ranging from the mid-to-high twenties, suggesting a deliberate exit rather than a panic liquidation. This is significant because Woodruff holds a senior operational role as CSO—someone with direct visibility into the company's scientific progress and pipeline—making her decision to trim substantially noteworthy. The context is critical: MapLight is an unprofitable biotech company posting significant quarterly losses, and a senior scientist's decision to reduce exposure during a period of negative earnings deserves scrutiny about what she may know regarding near-term prospects or personal financial priorities. Without visibility into her trading history or the broader insider activity at the company, the core question for investors is whether this represents rational portfolio rebalancing or a signal of diminished conviction in the company's direction.

CEO Christopher Kroeger sells ~50K shares across 8 transactions totaling $1.41M; fourth consecutive sale in 36 months amid mixed timing history.

Christopher Kroeger, MapLight's CEO, disposed of approximately 50,000 shares in eight separate transactions over three trading days, generating $1.41M in proceeds. This represents his fourth through eleventh open-market sales in the past 36 months—a sustained pattern of dispositions rather than an isolated event. Critically, his prior two evaluable sales at this stock were both poorly timed: the stock rose after each exit, meaning Kroeger was selling into weakness rather than ahead of declines. The company itself is loss-making with significant quarterly cash burn, so the timing misses on his prior sales are particularly noteworthy—the stock recovered despite deteriorating fundamentals. The shares were sold at prices ranging from the low-to-mid $27 range through the high $20s, while the stock now trades around $30 per share, approaching its 52-week highs after a strong recent run. Kroeger's repeated selling despite poor prior timing and the company's unprofitable state suggests either structural liquidity needs or a disconnect between his exit decisions and subsequent market performance.

MapLight Chief Discovery Officer Kreitzer sells 45,422 shares worth $1.35M as stock surges

Kreitzer Anatol, MapLight's Chief Discovery Officer, executed a substantial liquidation of 45,422 shares across three tranches, totaling approximately $1.35 million, on a single day as the stock rallied sharply. The company is unprofitable with significant operating losses, and Kreitzer's sale occurred while the stock was recovering from a deep trough—recently rebounding strongly but still trading below its recent highs. This represents meaningful position reduction by an officer with direct knowledge of drug discovery operations, though the timing during a strong price recovery suggests profit-taking rather than distress selling. The liquidation's size and concentration in one trading day, combined with the company's ongoing path to profitability, warrants scrutiny into whether this reflects confidence in near-term catalysts or confidence in the recent appreciation itself.

MPLT Chief Financial Officer Jonathan Gillis sells 69,835 shares across 5 transactions for $2,087,687.49 under pre-arranged 10b5-1 plan

Jonathan Gillis, serving as both CAAO and PAO at MapLight Therapeutics, executed 5 separate sales totaling 69,835 shares for $2,087,687.49 on 2026-04-27 and 2026-04-28, reducing his holdings from 251,054 shares to 181,219 shares (a -27.8% reduction). The sales were executed at prices ranging from $28.94 to $30.83, with a blended average price of $29.89. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-26, meaning the sales were scheduled and automatic rather than discretionary. As a Rule 10b5-1 plan transaction, the timing and execution reflect a pre-determined schedule rather than a current market judgment, limiting the inferential value of the sale pattern itself.

Director Pavlov George purchases 25,000 shares across 3 transactions for $441,167.58 at MPLT, establishing 25.0K share position

Director Pavlov George executed 3 separate purchases totaling 25,000 shares for $441,167.58 between February 18–20, 2026, at prices ranging from $17.48 to $17.86 (blended average $17.65), establishing his first recorded position at MapLight Therapeutics. The transactions occurred in a stock trading near the midpoint of its 52-week range ($12.81–$21.08) and showing recent positive momentum: +5.5% over 30 days and +27.8% over 90 days. However, MapLight faces material financial headwinds, reporting net income of $-29,418,000.00, and the stock trades at a market cap of $811,269,830.04, making the scale and rationale for the director's entry position merit closer scrutiny.